Cannabidiol inhibits SARS‐Cov ‐2 spike (S) protein‐induced cytotoxicity and inflammation through a PPARγ ‐dependent TLR4 / NLRP3 /Caspase‐1 signaling suppression in Caco‐2 cell line

GI-COVID: Are There COVID-19 Patients with Primary Gastrointestinal SARS-CoV-2 Infection and Symptoms?

(2021) John Ong et al.   DIGESTIVE DISEASES AND SCIENCES

Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages

(2021) Seegehalli M. Anil et al.   Scientific Reports

Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19

(2021) Barbara Malinowska et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

CANNABIDIOL ENHANCES INTESTINAL CB2 RECEPTOR EXPRESSION AND ACTIVATION INCREASING REGULATORY T CELLS AND REDUCES MURINE ACUTE GRAFT-VERSUS-HOST DISEASE WITHOUT INTERFERING WITH THE GRAFT-VERSUS-LEUKEMIA RESPONSE

(2021) Bárbara Betônico Berg et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

SARS-CoV-2 spike protein interacts with and activates TLR41

(2021) Yingchi Zhao et al.   CELL RESEARCH

Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019

(2021) Maurizio Bifulco et al.   Frontiers in Pharmacology

Cannabidiol Isolated From Cannabis sativa L. Protects Intestinal Barrier From In Vitro Inflammation and Oxidative Stress

(2021) Veronica Cocetta et al.   Frontiers in Pharmacology

Ultramicronized Palmitoylethanolamide Inhibits NLRP3 Inflammasome Expression and Pro-Inflammatory Response Activated by SARS-CoV-2 Spike Protein in Cultured Murine Alveolar Macrophages

(2021) Alessandro Del Re et al.   Metabolites

Can the enteric nervous system be an alternative entrance door in SARS-CoV2 neuroinvasion?

(2020) Giuseppe Esposito et al.   BRAIN BEHAVIOR AND IMMUNITY

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

Clinical Insights into the Gastrointestinal Manifestations of COVID-19

(2020) Jonathan Kopel et al.   DIGESTIVE DISEASES AND SCIENCES

Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process

(2020) Hao Zhang et al.   GUT

Activation of CB1R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury

(2020) Jérémie Joffre et al.   JOURNAL OF IMMUNOLOGY

Organoids demonstrate gut infection by SARS-CoV-2

(2020) Iain Dickson   Nature Reviews Gastroenterology & Hepatology

The potential of cannabidiol in the COVID‐19 pandemic

(2020) Giuseppe Esposito et al.   BRITISH JOURNAL OF PHARMACOLOGY

Direct endothelial damage and vasculitis due to SARS‐CoV‐2 in small bowel submucosa of COVID‐19 patient with diarrhea

(2020) Sergio Carnevale et al.   JOURNAL OF MEDICAL VIROLOGY

Specific re-distribution of SARS-CoV-2 variants in the respiratory system and intestinal tract

(2020) Pengcheng Du et al.   CLINICAL INFECTIOUS DISEASES

A molecular basis for the anti‐inflammatory and anti‐fibrosis properties of cannabidiol

(2020) Falone Sunda et al.   FASEB JOURNAL

Cannabidiol (CBD) modulation of apelin in acute respiratory distress syndrome

(2020) Évila Lopes Salles et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The Essential Medicinal Chemistry of Cannabidiol (CBD)

(2020) Kathryn M. Nelson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Immunological co-ordination between gut and lungs in SARS-CoV-2 infection

(2020) Shruti Ahlawat et al.   VIRUS RESEARCH

Differentiated Caco-2 cell models in food-intestine interaction study: Current applications and future trends

(2020) Xiaomeng Ding et al.   TRENDS IN FOOD SCIENCE & TECHNOLOGY

COVID-19 vaccines: The status and perspectives in delivery points of view

(2020) Jee Young Chung et al.   ADVANCED DRUG DELIVERY REVIEWS

A systematic review of cannabidiol dosing in clinical populations

(2019) S.A. Millar et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation

(2019) Nathan Kelley et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Paeoniflorin Prevents Intestinal Barrier Disruption and Inhibits Lipopolysaccharide (LPS)-Induced Inflammation in Caco-2 Cell Monolayers

(2019) Xi-Xi Wu et al.   INFLAMMATION

Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells

(2017) Stefano Gigli et al.   United European Gastroenterology Journal

Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS

(2016) Yong Hwan Park et al.   NATURE IMMUNOLOGY

Palmitoylethanolamide Exerts Antiproliferative Effect and Downregulates VEGF Signaling in Caco-2 Human Colon Carcinoma Cell Line Through a Selective PPAR-α-Dependent Inhibition of Akt/mTOR Pathway

(2016) Giovanni Sarnelli et al.   PHYTOTHERAPY RESEARCH

Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: Role for the adenosine A2A receptor

(2012) Alison Ribeiro et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Cannabidiol Reduces Intestinal Inflammation through the Control of Neuroimmune Axis

(2011) Daniele De Filippis et al.   PLoS One

Pharmacological Effects of Cannabinoids on the Caco-2 Cell Culture Model of Intestinal Permeability

(2010) A. Alhamoruni et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Cannabinoids and the gut: New developments and emerging concepts

(2010) Angelo A. Izzo et al.   PHARMACOLOGY & THERAPEUTICS

Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease

(2009) S.E. O'Sullivan et al.   IMMUNOBIOLOGY